Iconic Therapeutics

Iconic Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to translating the understanding of tissue factor biology into new therapies for retinal diseases and cancer. The company's lead candidate product, ICON-1, is a novel fusion protein designed to address the underlying causes of AMD-related vision loss. Iconic has completed a Phase 1 clinical trial in wet AMD and has initiated a Phase 2a study in newly diagnosed AMD patients. The company is also exploring the ICON protein family in cancer and has launched a solid tumor research program.